$
5.270
+0.17(3.333%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.300
Open
5.070
VWAP
5.08
Vol
1.81M
Mkt Cap
289.58M
Low
4.870
Amount
9.18M
EV/EBITDA(TTM)
--
Total Shares
25.33M
EV
241.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Show More
9 Analyst Rating
up Image
189.37% Upside
Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.25 USD with a low forecast of 12.00 USD and a high forecast of 20.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
up Image
189.37% Upside
Current: 5.270
sliders
Low
12.00
Averages
15.25
High
20.00
RBC Capital
Outperform
to
NULL
downgrade
$16 -> $12
2025-06-25
Reason
RBC Capital lowered the firm's price target on Verastem to $12 from $16 and keeps an Outperform rating on the shares. The firm is updating its model after the approval of Av-Fak, ASCO data for Av-Fak in PDAC, and data from partnered G12D, the analyst tells investors in a research note. RBC adds that it sees significant upside in the pipeline, with potential for label expansions into PDAC or NSCLC.
H.C. Wainwright
Sean Lee
Buy
upgrade
$10 -> $14
2025-05-09
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Verastem to $14 from $10 and keeps a Buy rating on the shares after the company's avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
RBC Capital
Gregory Renza
Outperform
maintain
$14 -> $16
2025-05-09
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on Verastem to $16 from $14 and keeps an Outperform rating on the shares. The approval of Avmapki Fakzynja Co-Pack has transformed Verastem into a commercial-stage company with the first FDA-approved drug in LGSOC, low-grade serous ovarian cancer, and the launch blueprint with key strategic imperatives and a pricing model are well-thought-out and supported by reasonable analogs, the analyst tells investors in a research note.
Jefferies
Kelly Shi
Buy
maintain
$15 -> $19
2025-05-08
Reason
Jefferies
Kelly Shi
Strong Buy
Initiates
$15
2025-04-10
Reason
Mizuho
Mara Goldstein
Buy
Maintains
$9 → $8
2025-04-09
Reason
Mizuho analyst Graig Suvannavejh yesterday lowered the firm's price target on Verastem to $8 from $9 and keeps an Outperform rating on the shares. The firm updated the company's model ahead of an expected product launch for avutometinib plus defactinib in low grade serous ovarian cancer.

Valuation Metrics

The current forward P/E ratio for Verastem Inc (VSTM.O) is -1.82, compared to its 5-year average forward P/E of -5.33. For a more detailed relative valuation and DCF analysis to assess Verastem Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.33
Current PE
-1.82
Overvalued PE
2.15
Undervalued PE
-12.81

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.42
Undervalued EV/EBITDA
-0.75

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
656.38
Current PS
9.56
Overvalued PS
2436.77
Undervalued PS
-1124.00

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+57.43%
-44.17M
Operating Profit
FY2025Q1
YoY :
+53.86%
-52.10M
Net Income after Tax
FY2025Q1
YoY :
-23.81%
-0.96
EPS - Diluted
FY2025Q1
YoY :
+36.53%
-38.68M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
693.0K
USD
9
3-6
Months
13.3K
USD
6
6-9
Months
56.4K
USD
11
0-12
Months
5.3K
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
7.7K
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1120.13% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
1
6-9
Months
643.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
4.8M
Volume
Months
6-9
1
397.5K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

VSTM News & Events

Events Timeline

2025-07-11 (ET)
2025-07-11
16:26:53
Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology
select
2025-06-30 (ET)
2025-06-30
16:02:58
Verastem announces Nature Medicine publication of FRAME results
select
2025-06-24 (ET)
2025-06-24
16:04:10
Verastem announces first patient dosed with VS-7375
select
Sign Up For More Events

News

9.0
07-11Newsfilter
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
5.0
07-08Newsfilter
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9.0
07-08Globenewswire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Sign Up For More News

FAQ

arrow icon

What is Verastem Inc (VSTM) stock price today?

The current price of VSTM is 5.27 USD — it has increased 3.33 % in the last trading day.

arrow icon

What is Verastem Inc (VSTM)'s business?

arrow icon

What is the price predicton of VSTM Stock?

arrow icon

What is Verastem Inc (VSTM)'s revenue for the last quarter?

arrow icon

What is Verastem Inc (VSTM)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Verastem Inc (VSTM)'s fundamentals?

arrow icon

How many employees does Verastem Inc (VSTM). have?

arrow icon

What is Verastem Inc (VSTM) market cap?